The University of Illinois at Chicago College of Pharmacy has received a $2.2 million federal grant to develop therapeutics to suppress the cravings of cocaine addicts.
Compounds developed by a research team led by Alan Kozikowski, professor of medicinal chemistry and pharmacognosy, will target one particular family of serotonin receptors in the brain. Recent evidence, he said, strongly suggests that these receptors, called 5-HT2 receptors, are important in controlling a person's desire to use drugs.
Researchers looking for therapies for cocaine addiction have largely overlooked the 5-HT2 receptor as a target, Kozikowski said, and focused on dopamine receptors instead.
"In large part, the field of cocaine medications research has been dominated by the so-called 'dopamine hypothesis,' where cocaine is known to block the re-uptake of the neurotransmitter dopamine.
"The higher levels of dopamine present in the cleft between neighboring neurons leads to cocaine's high," Kozikowski said. "This has led to years of work on the discovery of compounds that might displace cocaine from its binding site on the dopamine transporter, while still allowing dopamine to be taken up through the transporter.
"Success with this particular approach has been marginal at best."
The new target is a broad group of receptors that bind serotonin, also called 5-HT for its chemical name, 5-hydroxytryptamine. It is a neurotransmitter that controls a wide variety of behaviors, including anger, cognition, sleep, attention, sexuality and appetite. Low levels of serotonin may be associated with many health disorders, including clinical depression, obsessive-compulsive disorder, migraine headaches, irritable bowel syndrome and bipolar disorder.
The mode of action of 5-HT is complex, and at least seven different receptor 'families' are known, each located in various parts of the body and triggering different responses. Kozikowski's te
|Contact: Sam Hostettler|
University of Illinois at Chicago